Free press releases distribution network?

More news: Health/Surgery
Agency / Source: General Electric Company

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



GE Global Research, DARPA Partner on $2.9 MM Project to Study New Treatments for Diabetes - GE researchers will be demonstrating the technology this week at DARPA’s D60 symposium in Washington, DC - DARPA.mil / GEGlobalResearch.com.com
GE Global Research, DARPA Partner on $2.9 MM Project to Study New Treatments for Diabetes

 

PRTODAY - Newswire & PRZOOM/ - Niskayuna, NY, United States, 09/05/2018 - GE researchers will be demonstrating the technology this week at DARPA’s D60 symposium in Washington, DC - DARPA.mil / GEGlobalResearch.com.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• GE researchers to demonstrate concepts around neuromodulation technology to treat Diabetes during DARPA’s D60 Conference;
• Emerging scientific evidence shows that nervous system dysfunction may be a key contributor to many chronic diseases;
• Promising research in bioelectronic medicine suggests that stimulating and monitoring the human nervous system could create new treatments that replace drugs.

Could non-invasive devices replace drugs and regular insulin injections in the future treatment of diabetes? This is a central question a team of GE scientists are exploring as part of a research project with DARPA (darpa.mil) worth up to $2.9 million. GE researchers will be demonstrating the technology this week at DARPA’s D60 symposium in Washington, DC.

As part of the 3-year program, the GE Bioelectronic medicine team aims to demonstrate that a novel, non-invasive, stimulation technique can be used to reverse or treat diabetes in pre-clinical models, instead of the typical drugs associated with treatments today. The team hopes that the results indicate the ability to prevent the onset of metabolic dysfunction (associated with the onset of diabetes), and that the GE team can progress toward safely testing and applying this technology in the clinic.

“Today’s drug treatments and monitoring methods for diabetes can be uncomfortable and time consuming, and create side-effects for patients,” said Victoria Cotero, a PhD and Biologist at GE Global Research who contributes to the DARPA project. “Our project with DARPA aims to find a better alternative that treats diabetes with non-invasive medical devices without the side effects associated with drug treatments.”

This project is part of a growing body of research in the field of bioelectronic medicine that is exploring new ways to treat chronic diseases such as diabetes by using electronic devices to correct dysfunctions in the nervous system that are believed to be key contributing factors to these diseases. GE scientists have developed a novel, potentially breakthrough approach that could restore nerve signals to a healthy state using non-invasive devices that stimulate metabolic biosystems and produce drug-like effects, but with greater precision than traditional treatments, and with fewer side effects.

The GE Bioelectronic medicine team is located at GE’s Global Research Center in Upstate New York. This interdisciplinary team of scientists and engineers works at the intersection of biology, physics and engineering and has deep connections to other top academic and clinical collaborators in the field.

Recently, members of the GE team were part of groundbreaking work led by the Feinstein Institute for Medical Research to read and interpret nerve signals in the body. The projects with DARPA and Feinstein are part of a growing number of research initiatives that the Bioelectronic medicine team is exploring to transform the diagnosis, treatment and monitoring of diseases.

“Given GE’s decades of innovation in medical imaging modalities, our growing body of research and published work in biomedical research and our considerable network of academic and clinical collaborators, GE Global Research is in a unique position to help drive the emerging field of non-invasive neuromodulation and enable revolutionary new treatments for diabetes and other chronic diseases,” Chris Puleo, a GE biomedical engineer and principal investigator of the DARPA project said.

About GE Global Research

GE Global Research (geglobalresearch.com) is GE’s innovation powerhouse where research meets reality. We are a world-class team of 1,000+ scientific, engineering and marketing minds (600+ Ph. Ds), working at the intersection of physics and markets, physical and digital technologies, and across a broad set of industries to deliver world-changing innovations and capabilities for our customers.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+] [Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


GE Global Research, DARPA Partner on $2.9 MM Project to Study New Treatments for Diabetes

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
|
Contact: Todd Alhart - GE.com 
518-387-7914 todd.alhart[.]ge.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Health/Surgery via RSS
AddThis press release: GE Global Research, DARPA Partner on $2.9 MM Project to Study New Treatments for DiabetesAdd Health/Surgery News to My MSNAdd Health/Surgery News to My Yahoo!Add NewswireToday Health/Surgery Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From General Electric Company / Company Profile



Read Health/Surgery Most Recent Related Press Releases:

BeiGene Selects GE Healthcare’s Off-the-Shelf Biologics Factory to Boost its Manufacturing Capacity for Cancer Drugs
NEOFECT Commended by Frost & Sullivan for Introducing NEOFECT RAPAEL, its Gamification-based Smart Rehabilitation Solutions
Supportive Regulation and Funding Models Required to Advance Population Health Management in Asia-Pacific Says Frost & Sullivan
South Carolina's Moterum Technologies Selected to Present at Prestigious Cavendish BioHealth Forum
Massachusetts Tech, Innovation, and Aging Service Leaders Launch Global Competition to Improve Healthy Aging
US Acute Care Solutions Expands Relationship with Centura Health
mHealth for Diabetes and Heart Failure Will Revolutionize the Cardiometabolic Market Finds Frost & Sullivan
DiscGenics Engages CCRM and GE Healthcare to Support Scale-up Efforts for New Cell Therapy
SCBIO Presents PitchRounds At SEMDA MedTech Conference - South Carolina Inventors Convene to Present
Veritas Capital to Acquire Revenue-Cycle, Ambulatory Care and Workforce Management Software Unit from GE Healthcare for $1 Billion

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  JobsWare.com

Visit Reverie Language Technologies (P) Ltd

Visit  BizJobs.com





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)